RT Journal Article
SR Electronic
T1 Kyleena – another levonorgestrel IUS
JF Drug and Therapeutics Bulletin
JO Drug Ther Bull
FD BMJ Publishing Group Ltd
SP 18
OP 20
DO 10.1136/dtb.2018.2.0587
VO 56
IS 2
YR 2018
UL http://dtb.bmj.com/content/56/2/18.abstract
AB A levonorgestrel (LNG) intrauterine system (IUS) known as Kyleena (Bayer PLC) received marketing authorisation from the European Medicines Agency in 2016.1 The device contains 19.5mg LNG and is licensed for contraception for up to 5 years. This is the fourth LNG IUS product to be licensed for use in the UK. The company states that Kyleena offers advantages over Mirena and Jaydess LNG IUS devices.2 Here we consider the evidence for Kyleena.